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Liquid biopsies to genotype the epidermal growth factor receptor (EGFR) for targeted therapy have been implemented in clinical
decision-making in the field of lung cancer, but harmonization of detection methods is still scarce among clinical laboratories. We
performed a pilot external quality assurance (EQA) scheme to harmonize circulating tumor DNA testing among laboratories. For
EQA, we created materials containing different levels of spiked cell-free DNA (cfDNA) in normal plasma. The limit of detection
(LOD) of the cobas EGFR Mutation Test v2 (Roche Molecular Systems) was also evaluated. From November 2016 to June 2017,
seven clinical diagnostic laboratories participated in the EQA program. The majority (98.94%) of results obtained using the cobas
assay and next-generation sequencing (NGS) were acceptable. Quantitative results from the cobas assay were positively correlated
with allele frequencies derived from digital droplet PCR measurements and showed good reproducibility among laboratories. The
LOD of the cobas assay was 5∼27 copies/mL for p.E746 A750del (exon 19 deletion), 35∼70 copies/mL for p.L858R, 18∼36 copies/mL
for p.T790M, and 15∼31 copies/mL for p.A767 V769dup (exon 20 insertion). Deep sequencing of materials (>100,000X depth of
coverage) resulted in detection of low-level targets present at frequencies of 0.06∼0.13%. Our results indicate that the cobas assay
is a reliable and rapid method for detecting EGFRmutations in plasma cfDNA. Careful interpretation is particularly important for
p.T790M detection in the setting of relapse. Individual laboratories should optimize NGS performance to maximize clinical utility.
1. Introduction
Circulating tumor DNA (ctDNA) carries the samemolecular
alterations as the tumor itself and can be used to select
treatment, assess the emergence of drug resistance, and
monitor lung cancer patients in routine clinical practice
[1]. The fraction of tumor-derived cell-free DNA (cfDNA)
in blood plasma varies according to tumor stage, tumor
burden, vascularization of the tumor, biological features
of the tumor such as apoptotic rate, and the metastatic
potential of the cancer cells [2]. Tumor-derived ctDNA often
represents a small percentage of the total cfDNA and can
be present at allele fractions as low as 0.01% [3]. Therefore,
highly sensitivemethodologies have been developed to detect
low abundance epidermal growth factor receptor (EGFR)
mutations, including p.T790M, from cfDNA in non-small cell
lung cancer (NSCLC) patients, although the sensitivities and
specificities of the methods vary [4, 5].
A sensitive method is needed to detect the p.T790M
mutation in relapsed tumors because of tumor heterogeneity
[6]. Recently, several in vitro diagnostics (IVD) have been
approved by the European Medicines Agency (EMA) and
the US Food and Drug Administration (FDA) for detecting
EGFR mutations in plasma [7]. To ensure optimal quality
molecular testing, clinical laboratories should evaluate the
technical performance of ctDNA testing according to the
standards from formal accreditation bodies, such as Clinical
Laboratory Improvement Amendments (CLIA) and ISO
15189 [8, 9]. External quality assessment (EQA) is a way
to standardize interlaboratory results and to monitor and
improve testing processes across laboratories [10].
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In this study, we designed EQA materials to evaluate the
limit of detection (LOD) of the cobas EGFR Mutation Test
v2 (Roche Molecular Systems, Inc., Branchburg, NJ, USA)
andOncomine Lung cfDNAAssay (Thermo Fisher Scientific,
Waltham, MA, USA). We also implemented a pilot EQA
scheme to assess the interlaboratory comparability of plasma
EGFR testing results.
2. Materials and Methods
2.1. Preparation of EQA Materials
2.1.1. Pooled Normal Human Plasma (NHP) Preparation. The
workflowof the study process is shown in Supplementary Fig-
ure S1. Pooled normal human K2 EDTA plasma (NHP) was
prepared using residual specimens from healthy individuals
and was separated within 4 hours of collection. Negativity
for EGFR mutation of 2mL NHP was confirmed using the
cobas EGFR Mutation Test v2 (Roche Molecular Systems,
Inc.). cfDNA was extracted from 2mL NHP using the
MagMAXCell-Free DNA Isolation Kit (Thermo Fisher Sci-
entific) according to the manufacturer’s instructions. cfDNA
concentration and fragment size distribution were assessed
using a 2200 TapeStation Instrument (Agilent Technologies,
Santa Clara, CA, USA) with the Agilent D1000 ScreenTape
System.Average fragment sizewas 185 bp, and average cfDNA
concentration was 0.106 ng/𝜇L.We calculated that there were
1,162 wild-type copies per 2mL NHP.
2.1.2. EQA Material to Evaluate Assay Sensitivity. To prepare
spiked materials with known mutant allele frequencies and
mutant DNA copies, Multiplex I cfDNA Reference Standards
(Horizon Discovery, Cambridge, UK) were purchased. This
set is composed of wild-type cfDNA with mutant allele
frequencies of 5%, 1%, 0.1%, and 0%. For each reference
standard, copies per 𝜇L of wild-type and mutant DNA were
measured using digital droplet PCR and compared with the
values provided by the manufacturer (Supplementary Table
S1).
Four levels (levels 1 to 4) of spikedNHP (2mLper sample)
were prepared to determine the LOD of the detection assays.
Intended mutant allele frequencies were 5%, 2.5%, 1%, and
0.1%, with 4 to 760 mutant copies in a background of about
10,000∼16,000 wild-type copies in a spiked NPH samples,
depending on the mutation. cfDNA was extracted from 2mL
spiked NHP using MagMAX Cell-Free DNA Isolation Kit
(Thermo Fisher Scientific). Concentration and fragment size
distribution of cfDNAwere assessed using a 2200TapeStation
Instrument (Agilent Technologies). Average fragment size
was about 190 bp, and the range of cfDNA was 60.42 ng to
80.18 ng. Details are provided in Supplementary Table S1.
2.1.3. EQA Material to Evaluate Assay Precision. Genomic
DNA from cell lines harboring mutations of the EGFR
gene including p.T790M (HD258), p.L858R (HD254), and
p.E746 A750del (HD251) were purchased fromHorizon Dis-
covery. To simulate the size distribution of cfDNA, each
genomic DNA was fragmented to about 180∼190 bp by
sonication using a Covaris M220 (330 sec, 0.2% duty, 50 peak
incident power, and 200 cycles/burst; Covaris Inc., Woburn,
MA, USA) (Supplementary Table S2 and Supplementary
Figure S2). Three spiked NHPs (1mL per sample) were
prepared to evaluate assay precision. Intended mutant allele
frequencies were about 5%, with 1,221 to 1,503 mutant copies
in a background of nearly 23,000∼30,000 wild-type copies in
spikedNPHsamples, depending on themutation. cfDNAwas
extracted from 1mL spiked NHP using MagMAX Cell-Free
DNA Isolation Kit (Thermo Fisher Scientific). Concentration
and fragment size distribution of cfDNA were assessed
using a 2200 TapeStation Instrument (Agilent Technologies
instructions). Average size was 190 bp, and the cfDNA con-
centration (ng/mL) was 74.5∼80.2. Details are provided in
Supplementary Table S2. Spiked NHPs were frozen at <
−70∘C until genotyping.
2.2. Validation of EQA Material for LOD Evaluation
2.2.1. cfDNA Extraction from Spiked NHP Samples. cfDNA
was extracted from spiked NHP samples using MagMAX
Cell-Free DNA Isolation Kit (Thermo Fisher Scientific) for
next-generation sequencing and the cobas cfDNA Sample
PreparationKit (RocheMolecular Systems, Inc.) for the cobas
EGFR assay. cfDNA concentration and purity were assessed
using a NanoDrop 1000 spectrometer (Thermo Scientific,
Waltham, MA, USA) and a Qubit 2.0 Fluorometer (Life
Technologies, Grand Island, NY, USA) using the Qubit
dsDNA HS Assay Kit. Size and amount of DNA fragments
were assessed using a 2200 TapeStation Instrument (Agilent
Technologies) with the Agilent D1000 ScreenTape System
(Agilent Technologies).
2.2.2. Evaluation of EQA Material Using Next-Generation
Sequencing. For next-generation sequencing (NGS), a library
was prepared using the Oncomine Lung cfDNA Assay and
quantitated using qPCR. Emulsion PCRwas performed using
the Ion Chef System and Ion AmpliSeq IC 200 Kit (all
Thermo Fisher Scientific). Barcoded libraries generated from
20 ng DNA per sample were loaded on an Ion 530 chip and
sequenced on the Ion S5 XL System using Ion 520 and Ion
530 Kit-Chef (all Thermo Fisher Scientific). Alignment to
the hg19 human reference genome and variant calling were
performed using Torrent Suite software (Thermo Fisher
Scientific). Variant annotation was performed using Ion
Reporter Software 5.2 (Thermo Fisher Scientific). Torrent
Suite software provides molecular coverage depth as well
as read coverage depth at target bases to increase detection
sensitivity for low-frequency variants [11, 12]. The manufac-
turer recommends a median read coverage >25,000X and
median molecular coverage >2,500X to detect a variant with
an allele frequency of 0.1%. Measured allele frequency (%)
was calculated as mutant coverage depth divided by total
coverage depth.
2.2.3. Evaluation of LOD Material Using Real-Time PCR.
For the cobas EGFR assay, 75 𝜇L DNA from each sample
was loaded into three reaction wells (25 𝜇L DNA per well).
Amplification and detection were performed using the cobas
z 480 analyzer (Roche Molecular Systems, Inc.). Data were
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Figure 1: Analytical sensitivity of the cobas EGFR assay for NHP spiked with five different levels of mutant cfDNA. Copy numbers and
frequencies of mutant alleles are provided in Supplementary Table S3. Dots in the figure represent negative measurement (ND) or the SQI
value of the positive measurement for (a) p.E746 A750del (exon 19 deletion), (b) p.L858R, (c) p.T790M, and (d) p.A767 V769dup (exon 20
insertion) mutations.
interpreted by the cobas z 480 software if positive and
negative controls showed valid results. When a mutation
was detected, semiquantitative index (SQI) values for each
mutation are reported automatically by the software using the
observed threshold cycle for the targetmutation.The SQIwas
developed tomeasure trends in the amount ofmutant cfDNA
in a patient [13].
The analytical performance of the cobas EGFR assay
was additionally evaluated using five NHP samples spiked
with different mutant allele frequencies that were made
using Multiplex I cfDNA Reference Standards (Horizon
Discovery, Cambridge, UK).These test samples had expected
mutant allele frequencies of 3.85∼5.19%, 1.94∼2.65%, 0.72∼
1.10%, 0.34∼0.51%, and 0.05∼0.12% (Supplementary Table
and Figure 1).
2.3. Distribution of EQA Material, Data Collection, and
Analysis. Each laboratory director requested the amount of
EQA material needed according to the number of methods
planned for plasma EGFR testing. The number of reactions
per test method among participating laboratories was 13.The
EQA material set comprised four samples (2mL, levels 1 to
4) with different mutant allele frequencies (5.0%, 2.5%, 1%,
and 0.1%) for LOD analysis, and three samples with different
EGFRmutations were also provided (1mL per a reaction, P-1
to P-3).
For each test method, one EQA material set with 2mL
of LOD materials (levels 1 to 4) and 3mL precision materials
(P-1 to P-3) were distributed to each participating laboratory.
Materials in barcoded K2 EDTA tubes were shipped to
laboratories at 4∘C along with a results datasheet to record
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qualitative results (detected or not detected) and quanti-
tative results (SQI value from the cobas EGFR assay and
total/mutant coverage depth from next-generation sequenc-
ing) for each mutation. Submitted qualitative results were
evaluated as acceptable (positive for expected mutations or
negative for unexpected mutations) or unacceptable (nega-
tive for expected mutations or positive for unexpected muta-
tions), according to the manufactured and validated target
mutations in this study (Table 1 and Supplementary Table
S2). LOD level 4 material, which had an expected mutant
allele frequency of 0.05∼0.12%, was not graded. For the cobas
assay, the mean, standard deviation, coefficient of variation
(CV), median value, minimum value, andmaximum value of
data from the peer group and the standard deviation index of
the data from the laboratory were provided in the evaluation
reports.
2.4. Statistical Analysis. Statistical analysis was performed
using SPSS Statistics version 24.0.0 (IBM Corp., Armonk,
NY, USA). Correlations between SQI from cobas assay and
mutant allele frequency were analyzed using Spearman rank-
correlation test. All 𝑝 values were two-sided, and values less
than 0.05 were considered significant.
3. Results
3.1. Validation of EQA Materials. EQA materials for LOD
evaluation were validated using the Oncomine Lung cfDNA
Assay and cobas EGFR Mutation Test (Table 1). In a
deep sequencing run, all four quality control samples were
sequenced with high median coverage depth of more than
86,321X. All target bases showed adequate coverage (>500X).
There was sufficient coverage at all target mutations to detect
variants with allele frequencies of 0.1% (2,236∼4,439X).
All targeted mutations were called in levels 1–4 materials
at similar allele frequencies to what were expected. cobas
assay detected not only all target mutations in levels 1–3
materials but also p.L858R (0.12% allele frequency) and
p.E746 A750del (exon 19 deletion; 0.10% allele frequency) in
level 4 material.
3.2. Analytical Sensitivity of Real-Time PCR. Analytical sen-
sitivity (LOD) of the cobas EGFR assay was assessed using
five NHP samples spiked with different amounts of mutated
targets (Figure 1 and Supplementary Table S3). Seven of nine
cobas assays (77.8%) detected the exon 19 deletion in Test 5
material. All eight measurements of Test 4 material detected
the exon 19 deletion. Six (75%), five (62.5%), and seven
(87.5%) of eight measurements detected p.L858R, p.T790M,
and p.A767 V769dup (exon 20 insertion) mutations in the
Test 4material, respectively.Therefore, the LODs of the cobas
EGFR assay were determined to be 5∼27 copies/mL for exon
19 deletion (0.1∼0.5% allele frequency), 35∼70 copies/mL for
p.L858R (0.4∼0.8% allele frequency), 18∼36 copies/mL for
p.T790M (0.4∼0.8% allele frequency), and 15∼31 copies/mL
for exon 20 insertion (0.3∼0.7% allele frequency). For all
mutations, SQI values from the cobas assay exhibited a
strong positive correlation with the expected mutant allele
frequencies derived from digital droplet PCR measurements
(Spearman rank-correlation coefficient, 0.823∼0.924; 𝑝 <
0.0001).
3.3. Pilot EQA Scheme. In November 2016, seven clinical lab-
oratories that perform plasma EGFR molecular testing were
recruited for the pilot EQA scheme (Table 2). In April 2017,
EQAmaterials were made and distributed to each laboratory.
Amonth after distributing the EQAmaterials, all results were
emailed from each laboratory to an organizing director. In
June 2017, evaluation reports were distributed to participating
laboratories. Plasma EGFR testing was performed using an
IVD assay and two laboratory-developed tests based onNGS:
the cobas EGFR assay (𝑛 = 7), the Oncomine Lung cfDNA
Assay on the Ion S5 XL (𝑛 = 1), and the QIAGEN GeneRead
QIAact Actionable Insights Tumor Panel (QIAGEN, Hilden,
Germany) on the GeneReader Platform (QIAGEN) (𝑛 = 1).
There were two unacceptable results for NGS of LOD level 3
material (Tables 3 and 5).
3.4. Interlaboratory Comparability of Real-Time PCR Results.
All results obtained using the cobas assay were concordant
except for detection of EGFR exon 19 deletion and p.L858R
in LOD level 4 material. Among seven laboratories, only
six laboratories had a positive result for exon 19 deletion
(detection rate 85.7%) and one laboratory had a positive
result for p.L858R (detection rate 14.8%) in level 4 material.
p.T790M and exon 20 insertion mutations were not detected
in LOD level 4 material by any of the laboratories. The
precision of SQI is summarized in Table 4. The cobas assay
generally showed good reproducibility with a CV between
1.29% and 7.35% for target mutations. However, for p.T790M
and exon 20 insertion, the CV for level 3 and/or level 4
materials (13.1% ∼30.98%) was poorer than for the other
mutations.
3.5. Interlaboratory Comparison of Next-Generation Sequenc-
ing Results. Mutant allele frequencies were calculated from
the submitted depth of coverage data from NGS (Table 5).
Results from two laboratories were consistent with the
expected mutant allele frequencies calculated from absolute
allele frequencies measured using digital droplet PCR. In
laboratory F (S5XL + Oncomine Lung cfDNA Assay), all
expected mutations were detected in level 3 material. Exon
19 deletion and exon 20 insertion mutations were detected at
0.15% (total read coverage depth of 73,836X) and 0.23% (total
read coverage depth of 49,234X) in level 4 material, respec-
tively. However, p.T790M and p.L858R mutations were not
detected, despite the fact that total read coverage depth was
not lower for these loci than other loci (65,455X for p.T790M
and 70,849X for p.L858R). In laboratory C (GeneReader
+ QIAGEN GeneRead QIAact Actionable Insights Tumor
Panel), p.T790M and exon 20 insertion mutations were not
detected in level 3 material (unacceptable result). None of the
four target mutations were detected in level 4 material.
4. Discussion
In this study, we prepared and validated EQA material for
EGFR mutation detection using cfDNA and evaluated the
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Table 2: Plasma EGFR genotyping methods by laboratories participating in pilot external quality assurance.
Laboratories
In vitro diagnostics Laboratory-developed tests
cobas z 480 + cobas EGFRMutation
Test v2
S5XL + Oncomine Lung cfDNA
Assay
GeneReader + QIAGEN GeneRead
QIAact Actionable Insights Tumor
Panel
A O
B O
C O O
D O
E O
F O O
G O
analytical sensitivity of the cobas EGFR assay. According to
the package insert, the LOD of the cobas assay using sheared
DNA with an average size of 220 bp is less than 0.1% (75
copies/mL for exon 19 deletion, 25 copies/mL for the exon
20 insertion, and 100 copies/mL for p.L858R and p.T790M).
In the present study, we confirmed the LODs of the cobas
assay for each target mutation. The analytical sensitivities of
the cobas assay were not identical for the different target
mutations, similar to previous reports [14, 15]. In our pilot
EQA, the cobas assay showed a higher detection rate and
lower imprecision for exon 19 deletion and p.L858R than for
p.T790M and exon 20 insertion. Similarly, in laboratory F
that used the Oncomine Lung cfDNA Assay, p.T790M and
p.L858R were not detected, despite adequate depth of cover-
age of the target site compared to other loci.This difference in
assay performance according to targetmutationmight be due
to the assay design and characteristics of the target regions
[14, 15]. This finding is an important issue for detection of
p.T790M inpatientswho show evidence of tumor progression
after prior EGFR-tyrosine kinase inhibitor (TKI) therapy.
Previous studies reported that it is challenging to detect the
p.T790M mutation in patients with acquired resistance to
prior EGFR-TKI therapy due to genomic heterogeneity [16,
17]. Therefore, caution is warranted in the setting of tumor
relapse, and additional efforts should be made to optimize
the experimental conditions to increase the sensitivity of
p.T790M detection.
In our pilot EQA, participating laboratories performed
one IVD assay (cobas EGFR assay) and two laboratory-
developed tests based on NGS. The cobas assay showed
reliable and robust test performance in all laboratories. SQI
showed a positive correlation with mutant allele frequency
derived from digital droplet PCRmeasurements.This finding
is consistent with that of a previous study that evaluated clini-
cal samples withNGS and the cobas assay [13].Moreover, SQI
from the cobas assay was reproducible among laboratories
in our pilot EQA. Therefore, SQI could be useful for patient
monitoring. About 3 hours of processing time is required
for DNA extraction, PCR amplification, and detection in the
cobas assay.Thus, this assay can be used for rapid and reliable
plasma ctDNA analysis in clinical diagnostic laboratories.
A limitation of this study is the small number of labo-
ratories that participated, especially laboratories performing
NGS. It was unclear whether unacceptable responses were
due to the performance of specific NGS methods or the
laboratory. However, coverage depth results from two labo-
ratories indicate that more read coverage depth is required to
detect low-frequency variants in samples. In our validation
experiment using the Oncomine Lung cfDNA Assay, all
mutationswere detected in level 4material when the coverage
depth was more than 100,000X. Our data and previous
reports indicate that high coverage depth is essential to
improve the detection of low-level targets [18, 19].
Another issue related to NGS is assay turn-around time
(TAT). TAT for EGFR testing for NSCLC patients is impor-
tant for drug selection. NGS generally requires more time
than IVD, although it differs depending on batch constitution
and the platform used. The two laboratories that performed
NGS also used an IVD assay. The main advantage of NGS
over IVD is scalability for type of mutation and target gene.
Using NGS, rare (e.g., the p.C797S resistance mutation [20])
or novel mutations in EGFR, as well as other genes, can be
identified [21]. Moreover, advanced NGS technology enables
detection of not only pointmutation but also gene fusions and
amplifications [22, 23].
In the era of companion diagnostics, more mutations
will be used as predictive markers to determine patient eligi-
bility for molecular-targeted therapies. As a result, rigorous
quality controls to avoid inappropriate patient treatment
will become increasingly important in clinical diagnostic
laboratories. EQA is critical for quality assurance and con-
tinuous improvement of individual laboratory performance
[9]. Recently, Haselmann et al. have reported EQA scheme
for ctDNA analysis of KRAS and BRAF genotyping, using
mutant allele frequency of 0%, 5%, and 10% samples [24].
Digital approaches revealed no error rate, although Sanger
sequencing revealed very high error rate around 20%. The
authors suggested that method sensitivity correlates with
diagnostic accuracy. Another EQA report for blood based
EGFR p.T790M testing included pyrosequencing, digital
PCR, and several allele-specific PCR platforms, using four
levels of spiked materials [25]. Although we used limited
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number of methods of two NGS and one IVD platform, we
suggested more delicate means of EQA workflow tailored
to ctDNA testing, using strictly designed low-level materials
to assess assay sensitivity and precision in individual labo-
ratories. Larger trial including more genotyping platforms
including digital PCR with our sample preparation protocol
is worthy of further investigation. In our pilot EQA, we used
spiked ctDNA samples, which will facilitate standardization
and improvement of ctDNA testing practices in clinical
diagnostic laboratories.
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